Terms: = Thyroid cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809 AND Treatment
166 results:
1. Augmented ERO1α upon mtorC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11.
Wang Z; Zong H; Liu W; Lin W; Sun A; Ding Z; Chen X; Wan X; Liu Y; Hu Z; Zhang H; Li H; Liu Y; Li D; Zhang S; Zha X
J Exp Clin Cancer Res; 2024 Apr; 43(1):112. PubMed ID: 38610018
[TBL] [Abstract] [Full Text] [Related]
2. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mtor signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
3. Deep response to a combination of mtor inhibitor temsirolimus and dual immunotherapy of nivolumab/ipilimumab in poorly differentiated thyroid carcinoma with
Oh Y; Park JH; Djunadi TA; Shah Z; Chung LI; Chae YK
Front Endocrinol (Lausanne); 2024; 15():1304188. PubMed ID: 38356955
[TBL] [Abstract] [Full Text] [Related]
4. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mtor pathway.
Zhang W; Tang X; Peng Y; Xu Y; Liu L; Liu S
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38334171
[TBL] [Abstract] [Full Text] [Related]
5. GLP-1 receptor agonist liraglutide inhibits the proliferation and migration of thyroid cancer cells.
Zhang X; Zhang L; Wang B; Zhang X; Gu L; Guo K; Zhang X; Zhou Z
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):221-225. PubMed ID: 38279433
[TBL] [Abstract] [Full Text] [Related]
6. Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1.
Guo Y; Cui J; Liang X; Chen T; Lu C; Peng T
Int Immunopharmacol; 2024 Jan; 127():111407. PubMed ID: 38134594
[TBL] [Abstract] [Full Text] [Related]
7. Identification of a Novel TSC2 c.170G>A Missense Variant: A Case Report and Elaboration on the Yield of Targeted Options against Tuberous Sclerosis Complex Manifestations.
Papageorgiou G; Skouteris N; Valavanis C; Stanc GM; Souka E; Charalampakis N
Rev Recent Clin Trials; 2023; 18(4):304-312. PubMed ID: 37877150
[TBL] [Abstract] [Full Text] [Related]
8. NAA20 recruits Rin2 and promotes triple-negative breast cancer progression by regulating Rab5A-mediated activation of EGFR signaling.
Qiao L; Dong C; Jia W; Ma B
Cell Signal; 2023 Dec; 112():110922. PubMed ID: 37827343
[TBL] [Abstract] [Full Text] [Related]
9. Study of the PI3K/Akt/mtor signaling pathway in vitro and molecular docking analysis of periplocin inhibits cell cycle progression and induces apoptosis in MDA-MB-231.
Liu X; Liu J; Yan B; Quan Z; Wang X; Ma Y; Alarfaj AA; Yan L
Environ Toxicol; 2024 Jan; 39(1):444-456. PubMed ID: 37792628
[TBL] [Abstract] [Full Text] [Related]
10. Spleen tyrosine kinase facilitates the progression of papillary thyroid cancer regulated by the hsa_circ_0006417/miR-377-3p axis.
Tan G; Zheng S; Zhou B; Mo Z; Zhang Q; Zhang D; Li A; Liu X
Environ Toxicol; 2024 Jan; 39(1):421-434. PubMed ID: 37792549
[TBL] [Abstract] [Full Text] [Related]
11. Nanotechnological Advancements for the Theranostic Intervention in Anaplastic thyroid cancer: Current Perspectives and Future Direction.
Uppalapati SS; Guha L; Kumar H; Mandoli A
Curr Cancer Drug Targets; 2024; 24(3):245-270. PubMed ID: 37424349
[TBL] [Abstract] [Full Text] [Related]
12. Antitumor Activity of Berberine by Activating Autophagy and Apoptosis in CAL-62 and BHT-101 Anaplastic thyroid Carcinoma Cell Lines.
Shi XZ; Zhao S; Wang Y; Wang MY; Su SW; Wu YZ; Xiong C
Drug Des Devel Ther; 2023; 17():1889-1906. PubMed ID: 37397788
[TBL] [Abstract] [Full Text] [Related]
13. Everolimus combined with PD-1 blockade inhibits progression of triple-negative breast cancer.
Li G; Hu J; Cho C; Cui J; Li A; Ren P; Zhou J; Wei W; Zhang T; Liu X; Liu W
Cell Signal; 2023 Sep; 109():110729. PubMed ID: 37257766
[TBL] [Abstract] [Full Text] [Related]
14. Core Target and Key Signal Pathway of Xiaoluo in the treatment of thyroid cancer.
Liang W; Zhang K; Sun Y; Chen L; Wang Z; Cheng W; Li W
Altern Ther Health Med; 2023 Jul; 29(5):400-409. PubMed ID: 37171951
[TBL] [Abstract] [Full Text] [Related]
15. Significance of miRNAs on the thyroid cancer progression and resistance to treatment with special attention to the role of cross-talk between signaling pathways.
Doghish AS; El-Mahdy HA; Ismail A; Hegazy M; Mokhtar MM; Elkhawaga SY; Elkady MA; Yehia AM; Elsakka EGE
Pathol Res Pract; 2023 Mar; 243():154371. PubMed ID: 36791561
[TBL] [Abstract] [Full Text] [Related]
16. S100A6 promotes the development of thyroid cancer and inhibits apoptosis of thyroid cancer cells through the PI3K/AKT/mtor pathway.
Chen B; Zheng D; Liu C; Bhandari A; Hirachan S; Shen C; Mainali S; Li H; Jiang W; Xu J; Zhang X; Tang K; Zhang W
Pathol Res Pract; 2023 Feb; 242():154325. PubMed ID: 36680929
[TBL] [Abstract] [Full Text] [Related]
17. Genomic Profiling Reveals the Variant Landscape of Sporadic Parathyroid Adenomas in Chinese Population.
Tao X; Xu T; Lin X; Xu S; Fan Y; Guo B; Deng X; Jiao Q; Chen L; Wei Z; Chen C; Yang W; Zhang Z; Yu X; Yue H
J Clin Endocrinol Metab; 2023 Jun; 108(7):1768-1775. PubMed ID: 36611251
[TBL] [Abstract] [Full Text] [Related]
18. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in thyroid Cells.
Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
[No Abstract] [Full Text] [Related]
19. 3'-epi-12β-hydroxyfroside-mediated autophagy degradation of RIPK1/RIPK3 necrosomes leads to anergy of immunogenic cell death in triple-negative breast cancer cells.
Huang FY; Dai SZ; Xu WT; Xiong W; Sun Y; Huang YH; Wang JY; Lin YY; Chen H; Tan GH; Zheng WP
Pharmacol Res; 2023 Jan; 187():106613. PubMed ID: 36535569
[TBL] [Abstract] [Full Text] [Related]
20. Dysregulated ceRNA network modulated by copy number variation-driven lncRNAs in breast cancer: A comprehensive analysis.
Zhu X; Song J; Wang M; Wang X; Lv L
J Gene Med; 2023 Mar; 25(3):e3471. PubMed ID: 36525372
[TBL] [Abstract] [Full Text] [Related]
[Next]
